BARCELONA, Spain, October 1, 2026 / PRNewswire / -- Veeva Systems (New York Stock Exchange ticker: VEEV) today announced that Servier has standardized its customer reference data using the Veeva OpenData in over 80 countries. Building on the global success of adopting Veeva Link Key People, this leading French pharmaceutical company managed by a foundation is unifying its customer reference data and establishing a consistent data foundation for expanding the application of AI.
The Liam Hanrahan director of Servier stated: "By leveraging Veeva OpenData to centralize our customer reference data, we are not only improving current processes but also building a global data foundation that supports AI. This will redefine the way we work. A unified global semantic layer, along with connections to Veeva Link, provides high-quality insights for our subsidiaries, helping us to reach the right medical professionals in each market, thereby increasing efficiency and driving the expansion of AI on a global scale."
Leveraging OpenData and Link Key People, Servier has equipped its global sales and medical teams with interconnected data, enabling the entire company to gain insights more quickly and take action more swiftly.
The person in charge and president of Veeva Link and OpenData stated: "In this industry, 89% of the AI projects are hindered by data issues. Servier has demonstrated strong industry leadership by adopting a unified, data-centric AI approach across various regions. With OpenData as its global data foundation, Servier can more effectively expand sales execution driven by AI."
Veeva OpenData is a part of Veeva Data Cloud, which also includes Veeva Link and Veeva Compass. OpenData can unify customer reference data on a global scale, replacing fragmented data silos and providing the consistency required for advanced analysis and AI.
About Veeva Systems
Veeva provides industry cloud solutions for the life sciences sector, covering applications, agency services, data management, and consulting services. Veeva is committed to innovation, product quality, and customer success, serving over 1500 clients ranging from the world's largest pharmaceutical companies to emerging biotech firms. As a public interest company, Veeva strives to balance the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, please visit veeva.com / eu.
Veeva Forward-looking Statements
This press release contains forward-looking statements regarding Veeva products and services, as well as the expected results or benefits from using such products and services. These statements are based on the company's current expectations. Actual results may differ significantly from those described in this press release, and the company has no obligation to update these statements. There are numerous risks that may have an adverse effect on the company's performance, including those identified in the company's 10-Q filing for the fiscal quarter ending July 31, 2026 (a summary of relevant risks can be found on pages 33 to 34), as well as in subsequent filings submitted to the U.S. Securities and Exchange Commission, which can be viewed at sec.gov.
